Jonathan Rubin - 02 Nov 2026 Form 4 Insider Report for SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Reporting relationship: SVP, Chief Medical Officer
Issuer ticker: SUPN
Reported as of: 02 Nov 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 04 Nov 2026, 16:31:09 UTC
Prior SEC filing: 02 Nov 2026
Source filing: View source filing
Reporting owner signature: /s/ Timothy C. Dec, as attorney-in-fact

Filing notes and source

Key filing fact

Jonathan Rubin filed Form 4 for SUPERNUS PHARMACEUTICALS, INC. (SUPN) on 04 Nov 2026.

Key facts

This page summarizes Jonathan Rubin's Form 4 filing for SUPERNUS PHARMACEUTICALS, INC. (SUPN).
15 reported transactions and 14 derivative rows are listed below.
Accepted by SEC: 04 Nov 2026, 16:31.

Change

Previous filing in this sequence was filed on 02 Nov 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001836067 Primary reporting owner

Rubin Jonathan

Relationship: SVP, Chief Medical Officer
Address: C/O SUPERNUS PHARMACEUTICALS, INC.,, 9715 KEY WEST AVENUE, ROCKVILLE
Signature: /s/ Timothy C. Dec, as attorney-in-fact
Signature date: 04 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SUPN transaction

Common Stock

Other

Transaction value
Shares: -13,979
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares: -15,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $23.99
Footnotes: F2, F3

SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares: -25,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $29.61
Footnotes: F2, F4

SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares: -25,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $32.20
Footnotes: F2, F5

SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares: -20,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $38.60
Footnotes: F2, F6

SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares: -25,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 25,000
Exercise price: $27.94
Footnotes: F2, F7

SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares: -20,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,000
Exercise price: $33.52
Footnotes: F2, F8

SUPN transaction Derivative

Employee Stock Option (Right to Buy)

Other

Transaction value
Shares: -13,500
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,500
Exercise price: $50.20
Footnotes: F2, F9

SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares: -70,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 70,000
Exercise price: $0.000000
Footnotes: F2, F10

SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares: -3,000
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price
Footnotes: F2, F11, F12

SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares: -3,375
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,375
Exercise price
Footnotes: F2, F11, F13

SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares: -2,500
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 2,500
Exercise price
Footnotes: F2, F11, F14

SUPN transaction Derivative

Restricted Stock Unit

Other

Transaction value
Shares: -1,250
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 1,250
Exercise price
Footnotes: F2, F11, F15

SUPN transaction Derivative

Performance Share Unit

Other

Transaction value
Shares: -4,250
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 4,250
Exercise price
Footnotes: F2, F16, F17

SUPN transaction Derivative

Performance Share Unit

Other

Transaction value
Shares: -3,500
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 02 Nov 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,500
Exercise price
Footnotes: F2, F16, F18

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Jonathan Rubin is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 18 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/26, Artemis Merger Sub Inc. merged with and into Supernus Pharmaceuticals, with Supernus Pharmaceuticals surviving as a wholly-owned subsidiary of Indivior. At the effective time, each outstanding share of Supernus Pharmaceuticals common stock was cancelled and automatically converted into the right to receive 1.5401 shares of Indivior common stock. In connection with the merger, Indivior changed its name to "Supernus, Inc." The reporting person's shares of Supernus Pharmaceuticals common stock were disposed of, and the shares of Supernus, Inc. common stock received in exchange were acquired, pursuant to the merger. The reporting person received no cash consideration other than cash in lieu of a fractional share.

Footnote F2

Pursuant to the Agreement and Plan of Merger, dated as of August 1, 2026, by and among Indivior Pharmaceuticals, Inc. ("Indivior"), Artemis Merger Sub Inc. and Supernus Pharmaceuticals, Inc. ("Supernus Pharmaceuticals"), at the effective time of the merger on 11/2/2026, each outstanding Supernus Pharmaceuticals equity award was assumed by Indivior (renamed Supernus, Inc.) and automatically converted into a corresponding Supernus, Inc. equity award covering the number of Supernus, Inc. shares equal to the number of Supernus Pharmaceuticals shares subject to the award multiplied by the 1.5401 exchange ratio (rounded down), with the per-share exercise price divided by the exchange ratio and rounded up to the nearest whole cent. Each converted award is subject to substantially the same terms and conditions, including vesting, that applied immediately prior to the effective time, except performance stock unit awards ceased were converted into time-vesting restricted stock units.

Footnote F3

The options vest in four equal installments beginning February 21, 2021.

Footnote F4

The option vests in four equal annual installments beginning on February 19, 2022.

Footnote F5

The option vests in four equal annual installments beginning on February 22, 2023.

Footnote F6

The option vests in four equal annual installments beginning on February 23, 2024.

Footnote F7

The option vests in four equal annual installments beginning on February 22, 2025.

Footnote F8

The option vests in four equal annual installments beginning on February 19, 2026.

Footnote F9

The option vests in four equal annual installments beginning on February 18, 2027.

Footnote F10

These restricted stock units ("RSUs") are settled in common stock upon vesting, which occurs in four installments. 50% of the RSUs vest upon the closing of the merger-of-equals transaction between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (the "Closing"). 15% of the RSUs vest upon the one-year anniversary of the Closing. 15% of the RSUs vest upon the two-year anniversary of the Closing. 20% of the RSUs vest upon the three-year anniversary of the Closing.

Footnote F11

Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F12

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 18, 2027.

Footnote F13

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 19, 2026.

Footnote F14

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025.

Footnote F15

These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 23, 2024.

Footnote F16

Each performance share unit represents the right to receive one share of Supernus common stock upon vesting.

Footnote F17

On February 19, 2025, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on May 3, 2025.

Footnote F18

On February 18, 2026, the Reporting Person was awarded Performance Share Units with individual performance objectives and a defined performance period established on July 15, 2026.